ClinicalTrials.gg
CompletedNCT04463056Updated Sep 1, 2021

Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

A Phase 3 interventional study of Elizaria® and Soliris® in Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome and Paroxysmal Hemoglobinuria, sponsored by AO GENERIUM. Completed at 4 sites in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by AO GENERIUM · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Nov 2017, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
10th of 18
32 · median 37
Started
2017
the only one that year
Phase 3
14 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
2 of 18
AO GENERIUM

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 14 in phase 3, and was the 13th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Elizaria® (eculizumab, GENERIUM JSC, Russia) versus Soliris® (Alexion Pharma GmbH, Switzerland) in patients with paroxysmal nocturnal hemoglobinuria.

Read the detailed description

After screening, patients meeting all of the inclusion / non-inclusion criteria and vaccinated against meningococcal infections were divided into two subgroups according to the eculizumab treatment status (Soliris® naïve patients / patients who had received Soliris® at a maintenance dose prior to the trial inclusion). Each subgroup included an even number of patients to maintain recruitment balance. Then, patients of each subgroup were distributed into one of two treatment groups by the method of stratified block randomization at a 1:1 ratio into groups A and B, respectively. In the first group (Group A), patients received infusions of Elizaria (eculizumab, GENERIUM JSC), in the second one (Group B) - infusions of Soliris®.

The duration of participation of each patient in the study, including the screening period, was about 30 weeks.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
  • Marchiafava-Micheli Syndrome
  • Paroxysmal Hemoglobinuria

Keywords

  • Paroxysmal Cold Hemoglobinuria
  • eculizumab
  • Complement Inactivating Agents
  • Hemolysis
  • Anemia, Hemolytic
  • Anemia
  • Hematologic Diseases
  • Bone Marrow Diseases
  • Hemoglobinuria
  • Proteinuria
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written for participation in the study.
  2. Men and women aged 18 to 65 years at the time of signing the Informed Consent Form.
  3. Established diagnosis of paroxysmal nocturnal hemoglobinuria (PNH), confirmed by flow cytometry assessing the PNH red blood cell and white blood cell clone size, with intravascular hemolysis and current or previous concomitant clinical symptoms, irrespective of the need for blood transfusions and without signs of other disorders associated with bone marrow failure.
  4. For patients, who have not received Soliris® before inclusion in this study: lactate dehydrogenase (LDH) level 1.5 times the or higher as assessed by the central laboratory.
  5. The patients receiving anticoagulants must take them at a stable dose for at least 4 weeks prior to screening. Patients receiving warfarin must have a stable (INR) value. To confirm INR value stability, the patients have to provide a blood INR test at least 4 weeks prior to screening. The second INR assessment will be performed at the screening visit.
  6. Documented vaccination against meningococcal infections (Neisseria meningitidis serogroups A, C, Y and W-135) the protective immunity of which did not wear off, at least 14 days prior to the administration of the first dose of the test or reference drug and the patient's consent for revaccination against meningococcal infections (Neisseria meningitidis serogroups A, C, Y and W-135) during participation in the current study if the protection from previous vaccination wears off.
  7. Subjects' consent to use reliable methods (the combination of at least 2 methods, including barrier contraception, for example, condoms with spermicide) from signing the Informed Consent Form for up to 10 weeks after stopping therapy.

Exclusion criteria

Exclusion Criteria:

  1. to the test drug, reference drug and their components.
  2. Hypersensitivity to the active substance or any other component of the vaccine used to prevent meningococcal infection or a lifethreatening reaction to a previously administered vaccine containing similar ingredients.
  3. Conditions associated with bone marrow failure and PNH clone (aplastic anemia, myelodysplastic syndrome, idiopathic myelofibrosis).
  4. A history of infections caused by Neisseria meningitides.
  5. Active systemic bacterial, viral, or fungal infection within 14 days prior to the administration of the first dose of the test or reference drug.
  6. Fever of 38°С or higher within 7 days prior to the administration of the first dose of the test or reference drug.
  7. Hereditary complement deficiencies.
  8. Patients planning to undergo or with a history of bone marrow transplantation.
  9. Initial treatment cycle (induction phase) of Soliris®; completed treatment with Soliris® less than 70 days before study inclusion, not related to the current study participation.
  10. Vaccination with any within 1 month prior to the administration of the first dose of the test or reference drug;
  11. Concomitant diseases and conditions which may, in the Investigator's opinion, compromise the patient's safety in case of participation in the study or which could affect the safety data analysis in case of an exacerbation of this disease/condition during the study, including the following:

    • Myocardial infarction or stroke within the last 3 months, severe arrhythmia, functional class III/IV heart failure;
    • Psychiatric disorders;
    • Immune and endocrine disorders which are not controlled with medications (including decompensated diabetes mellitus and thyroid disorders);
    • Hematologic disorders requiring chemotherapy;
    • Current or prior oncologic disorders, except for successfully treated basal cell carcinoma;
    • Decompensated liver diseases.
  12. Acquired immunodeficiency syndrome or (HIV) infection confirmed by test results.
  13. Active viral and/or C at screening with (ALT) and/or aspartate aminotransferase (AST) levels 5 times the or higher.
  14. Positive syphilis test results.
  15. (BMI) ≤17 kg/m2 or ≥30 kg/m2.
  16. Pregnancy or breastfeeding.
  17. History of tuberculosis, alcohol addiction, medication abuse, or drug addiction.
  18. Patient's participation in any clinical studies and/or using of not approved medications in the Russian federation within 30 days before screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Elizaria®

    International nonproprietary name: eculizumab

    Biological: Elizaria®

  • Active comparator
    Soliris®

    International nonproprietary name: eculizumab

    Biological: Soliris®

Interventions

  • BiologicalElizaria®

    Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.

    Also known as: eculizumab

  • BiologicalSoliris®

    Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.

    Also known as: eculizumab

06

What researchers measure

Primary outcomes

  1. Area under the LDH concentration-time curve (LDH AUC) during the maintenance therapy with the test drug or the reference drug

    Time frame: week 22

Secondary outcomes

  1. Area under the LDH concentration-time curve (LDH AUC) during 26-week therapy with the test product or the reference product

    Time frame: week 26

  2. Hemoglobin level change during the maintenance therapy with the test drug or the reference drug

    Time frame: week 22

  3. Number/proportion of the patients with stable hemoglobin level during the maintenance therapy with the test drug or the reference drug

    Time frame: week 22

  4. Number/proportion of patients with various thrombotic complications developing during treatment with the test product or the reference product.

    Time frame: week 26

  5. Number/proportion of patients who needed donor red blood cell transfusions during treatment with the test product or the reference product.

    Time frame: week 26

  6. Number of donor red blood cell transfusions during treatment with the test product or the reference product.

    Time frame: week 26

  7. Number/proportion of patients with breakthrough hemolysis

    Breakthrough hemolysis defined as at least one new episode or worsening of at least one previous signs of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, severe vascular complications (including thrombosis), dysphagia or erectile dysfunction) associated with increased LDH after a previous decrease during treatment.

    Time frame: week 26

07

Study locations

4 sites
  • Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia)
    Moscow, 125167, Russian Federation
  • Moscow State Budget Funded Healthcare Institution S. P. Botkin City Clinical Hospital, Moscow Department of Healthcare
    Moscow, 125284, Russian Federation
  • State Budget Funded Institution of Higher Education Academician I. P. Pavlov Saint-Petersburg State Medical University of the Ministry of Health of the Russian Federation
    Saint Petersburg, 197022, Russian Federation
  • State Budgetary Educational Institution of Higher Professional Education Samara State Medical University, Ministry of Health of the Russian Federation.
    Samara, 443079, Russian Federation
08

References and documents

Publications

  • Kulagin AD, Ptushkin VV, Lukina EA, Davydkin IL, Korobkin AV, Shamrai VS, Konstantinova TS, Kaporskaya TS, Mitina TA, Ksenzova TI, Zuev EV, Markova OA, Gapchenko EV, Kudlay DA. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol. 2021 Nov;100(11):2689-2698. doi: 10.1007/s00277-021-04624-7. Epub 2021 Aug 16. PubMed 34398258 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2018, 10 months.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 10 months is below that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2020
First posted
Jul 9, 2020
StartActual
Nov 29, 2017
Primary completionActual
Oct 16, 2018
CompletionActual
Oct 16, 2018
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04463056
Lead sponsor
AO GENERIUM
Responsible party
Sponsor
First posted
Jul 9, 2020
Start date
Nov 29, 2017
Primary completion
Oct 16, 2018
Completion
Oct 16, 2018
Last update
Sep 1, 2021

Study contacts

Oksana A. Markova, MD
study chair · AO GENERIUM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion